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Abstract Objective: To assess
the effects of intravenous fish oil
fat emulsion on the metabolic
alterations induced by lipopolysac-
charide (LPS) challenge in healthy
volunteers. Design: Two groups of
eight healthy subjects were random-
ized to receive either two pharma-
cological doses of intravenous FO
fat emulsion or no treatment. The
FO group received twice 0.5 g/kg
10% emulsion (Omegaven) 48
and 24 h before investigation. LPS
(2 ng/kg) was injected as a bolus
on the investigation day. Systemic
parameters, indirect calorimetry,
heart rate variability, and platelet
membrane phospholipid composi-
tion were measured. Results: Basal
EPA and DHA content in platelet
phospholipids was low (0.28% and
2.54%, respectively) and increased
significantly after FO to 1.68% and
3.32%. LPS induced reproducible
effects in all subjects. Fever was
higher in the FO group than in con-
trols; the difference was significant
from t120 until t360. FO blunted
the neuroendocrine response: the
rise in plasma norepinephrine was
sevenfold lower at t120 while the
ACTH peak was fourfold lower.
Tumor necrosis factor α was sig-
nificantly lower between t360 and
t180 in the FO group. Conclusions:
Two doses of intravenous FO fat
emulsion modified the phospholipid
composition of platelets in healthy
subjects. FO blunted fever and
increased the neuroendocrine and
the inflammatory responses to
LPS.
Keywords Endotoxin challenge ·
Lipopolysacharide · Fish oil sup-
plement · Cytokines · Inflammatory
response · Neuroendocrine response
Introduction
There are two main families of polyunsaturated fatty acids
(PUFAs) n-6 and n-3. Among the n-3 PUFA family EPA
and DHA are the most biologically active. Feeding with
fish oil (FO) increases the proportion of EPA and DHA
in the cell membrane phospholipids, including inflamma-
tory cells. This decreases the synthesis of inflammatory
eiconsanoids by numerous mechanisms [1]: (a) substrate
competition, (b) inhibition of membrane arachidonic
acid release, (c) synthesis of less potent eicosanoids, and
(d) downregulation of proinflammatory cytokines, adhe-
sion molecules, and of genes involved in inflammation.
It is generally considered that the oral administration of
n-3 PUFA is required for several weeks to produce
biological effects, precluding its use in acute conditions.
However, it has recently been observed that intravenous
administration of fat emulsions enriched with n-3 PUFA
leads to rapid incorporation of n-3 fatty acids into phos-
pholipids of platelets or monocytes [2]. Modulation of
the inflammatory response in septic patients is desirable
as excessive release of proinflammatory cytokines is
associated with multiple organ failure; FO may thus prove
to be a new therapeutic tool [3, 4].
Endotoxin (LPS) administration is an experimental, re-
producible model of sepsis, mimicking some important as-
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pects of sepsis, and has the advantage of being short lived.
This study examined whether two doses of intravenous FO
downregulates the neuroendocrine and systemic responses




After approval by the institutional ethics committee
and written informed consent we enrolled 16 men aged
18–35 years. Inclusion criteria were: good health, no med-
ication, low fish consumption (less than twice a week),
no nutritional supplementation, and particularly no FO
supplements. A complete history, physical examination,
and 12-lead electrocardiography were performed. Subjects
had a mean age of 26.2 ± 2.7 years, body weight of
77.4 ± 7.2 kg, and body mass index of 23.4 ± 1.9.
Study design and intervention
Subjects were randomized to receive two pharmacological
doses of intravenous FO 48 and 24 h before investiga-
tion, a dose of 5 ml/kg during 6 h each time (100 ml
Omegaven 10%: 10 g FO, providing 1.25–2.82 g EPA
n-3); 1.44–3.09 g DHA (n-3), 0.1–0.7 g linoleic acid
(n-6), max. 0.2 g α-linolenic acid (n-3) and 15.0–29.6 mg
α-tocopherol; Fresenius Kabi, Bad Homburg, Ger-
many). On the investigation day subjects came after
an overnight fast, and were requested to void (urine
discarded). Thereafter they remained recumbent for the
next 8 h. Two venous cannulas were inserted into the
forearms: one for labeled glucose infusion and one for
blood sampling. Blood samples were collected every
30–60 min. Endotoxin (2 ng/kg, USP Rockville, Md.,
USA; lot no. 2) was administered as an intravenous bolus
at time t0.
Blood collection and analysis
In subjects who received FO fat emulsion two series of
blood samples were collected (EDTA tubes): one before
the first infusion and the second 48 h later, before LPS.
Plasma was separated by low-speed centrifugation, and
supernatant was centrifuged at 3,000/min for 10 min
at 4 °C. After separation of platelet lipid components
by thin-layer chromatography the fatty acid pattern was
analyzed only in the phospholipid fraction since mainly
phospholipid fatty acids affect cell function. Triacyl-
glycerol, phospholipids, and cholesterylesters were first
separated by a two-dimension thin-layer chromatogra-
phy. Fatty acids were analyzed by gas chromatography
(Agilent, GC system, 6890A).
On the day of experiment blood was sampled dur-
ing the protocol to determine hormone levels (insulin,
glucagon, cortisol, ACTH, catecholamines), inflammatory
markers [tumor necrosis factor (TNF) α, interleukin
(IL) 6, hsCRP), glucose, lactate, free fatty acids (FFA),
and triglycerides. Plasma aliquots were stored at –20 °C
or –80 °C (for FFA determination). Plasma insulin
(Adaltis kit, Casalecchio di Reno, Italy), glucagon (Linco
Research, St. Charles, Mo., USA) and cortisol (Diagnostic
Products, Los Angeles, Calif., USA) were determined
by radioimmunoassay; ACTH by chemiluminescence
(Nichols Institute Diagnostics, San Juan Capistrano,
Calif., USA); TNF-α by photometric enzyme-linked
immunosorbent assay in streptavidin-coated microtiter
plates (Roche, Mannheim, Germany); IL-6 by enzyme
immunoassay using an enzyme-linked polyclonal antibody
specific for IL-6 (Quantikine, R&D Systems, Germany);
hsCRP by turbidimetry on a Hitachi 917 (Roche). Plasma
glucose and lactate concentrations were measured enzy-
matically (YSI 2300 STAT PLU, Yellow Spring, Ohio,
USA); plasma FFA concentrations with a colorimetric
method (Wako, Neuss, Germany). Urine was sampled
from spontaneous voiding. Indirect calorimetry was
performed using a canopy (Deltatrac2 model Datex,
Kuopio, Finland). Resting energy expenditure (REE)
was calculated from oxygen consumption (VO2) and
CO2 production (VCO2) using the Livesey and Elia [5]
equation.
Vital functions
Heart rate, respiratory rate, rectal temperature (Hellige,
Servomed, Germany), noninvasive arterial blood pressure
(Critikon Dinamap, Tampa, Fla., USA), cardiac output
(thoracic bioimpedance, NCCOM3 cardiodynamic mon-
itor, BoMed, Irvine Calif., USA) and transcutaneous
oxygen saturation (SpO2, Pulse oximeter Biox 3740,
Ohmeda, Engelwood, Calif., USA) were monitored.
Subjective symptoms such as muscle and head ache, and
nausea/vomiting were recorded.
Baroreflex sensitivity and heart rate variability
Baroreflex sensitivity was derived from the spontaneous
fluctuations in systolic blood pressure (SBP) and pulse
rate. We used the sequence technique, which focuses
on the baroreflex response to pressure transients [6, 7].
Blood pressure (BP) was measured continuously by
a Finapres BP Monitor (Ohmeda). SBP and pulse series
were scanned automatically in search for spontaneous
sequences of three or more consecutive heart beats in
which a progressive SBP increase was followed, with
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a one-beat lag, by a progressive pulse rate lengthening or
vice versa. The slope of the regression line between SBP
and pulse interval values forming each sequence was taken
as an estimation of the sensitivity of baroreflex cardiac
modulation.
ECG, BP, and respiration were recorded at a sampling
frequency of 200 Hz. Beat-to-beat series of R-R interval
were derived for heart rate variability (HRV) analysis as
were series of SBP and pulse rate for baroreflex sensitivity
estimation. Signals were edited manually from artifacts
such as movements and noise. Beat-to-beat series were
interpolated and resampled at 5 Hz to obtain an evenly
sampled series and then split into data segments of 120 s.
Segments were overlapped by 50% and a fast Fourier
transform spectrum was computed in each window. All
fast Fourier transform spectra were averaged to obtain
a single final spectrum, which was integrated over the low
(LF; 0.05–015 Hz) and high (HF; 0.15–0.50 Hz) frequency
bands to characterize the LF and HF powers and LF/HF
power ratio. Measures were recorded three times (30 min):
at baseline and at 120 and 360 min.
Statistical analysis
Results are given as means ± SD. One-way and two-way
analyses of variance for repeated measures (time, group,
and interaction) were used to compare groups where ap-
propriate. Differences with p value less than 0.05 were
considered statistically significant. Analyses used the sta-
tistical package JMP 5.1 (SAS Institute, Cary, N.C., USA).
Table 1 Effect of endotoxin on the systemic variables, baroreflex sensitivity, and heart rate variability
t0 t30 t60 t120 t180 t240 t360
Control
Temperature (◦C) 36.8 ± 0.3 – 36.9 ± 0.2 38.0 ± 0.5** 38.6 ± 0.5** 38.7 ± 0.3** 38.0 ± 0.3**
Heart rate (bpm) 59 ± 7 – 64 ± 6 75 ± 8** 87 ± 9** 88 ± 9** 82 ± 9**
Cardiac output (%) 100 – 96 ± 12 118 ± 16 131 ± 33* 140 ± 45** 125 ± 30*
Respiratory rate (bpm) 15 ± 1 – 15 ± 2 18 ± 2** 17 ± 3* 15 ± 2 13 ± 1
Baroreflex sensitivity – 12.25 ± 3.67 – 11.23 ± 4.61 – – 5.78 ± 2.04
(m s−1 mmHg−1)
LF (m s−2) – 1499 ± 1486 – 2134 ± 1226 – – 627 ± 538*
HF (m s−2) – 797 ± 845 – 753 ± 517 – – 144 ± 117*
LF/HF ratio – 2.0 ± 0.8 – 3.7 ± 1.5* – – 4.7 ± 1.6**
Fish oil
Temperature (◦C) 36.7 ± 0.1 – 36.8 ± 0.2 37.3 ± 0.3** 37.9 ± 0.3** 38.1 ± 0.2** 37.7 ± 0.3**
Heart rate (bpm) 63 ± 10 – 64 ± 7 78 ± 7** 89 ± 4** 88 ± 5** 78 ± 10**
Cardiac output (%) 100 – 101 ± 7 113 ± 18 137 ± 27** 134 ± 17* 121 ± 17*
Respiratory rate (bpm) 14 ± 2 – 14 ± 1 16 ± 2 16 ± 2 14 ± 1 14 ± 1
Baroreflex sensitivity – 12.37 ± 3.04 – 10.07 ± 5.68 – – 8.03 ± 2.42
(m s−1 mmHg−1)
LF (m s−2) – 1480 ± 1169 – 1884 ± 1966 – – 754 ± 592*
HF (m s−2) – 897 ± 780 – 751 ± 1068 – – 301 ± 394*
LF/HF ratio – 1.7 ± 0.7 – 3.2 ± 1.1* – – 3.8 ± 1.7*
* p < 0.05, ** p < 0.01 vs. baseline
Results
Physiological response to endotoxin
LPS induced reproducible systemic, endocrine, and
metabolic effects in both groups, starting about 75 min
after LPS injection (Table 1). All subjects complained of
headache, nausea, and muscle pain.
Systemic effects
Significant increases in body temperature (+1.9 °C,
p < 0.0001), heart rate (+52%, p < 0.0001), and cardiac
output (+40%, p < 0.0001), peaking at t240 after LPS were
observed in control subjects. Systolic, diastolic, mean
blood pressure, and SpO2 did not change significantly.
Hormones, cytokines, and metabolism
LPS induced a marked endocrine response in control
subjects (Table 2). At t240 ACTH levels were increased
15 times (p < 0.0001), cortisol 3 times (p < 0.0001),
and glucagon 60% (p = 0.012). Both plasma norepineph-
rine (peak at t120, +252%, p < 0.001) and epinephrine
(peak at t240, +117%, p < 0.002) increased strongly.
Insulin levels showed a temporary decrease at t120
and then reached basal levels. Following LPS TNF-α
levels increased 110 times at t120 (p < 0.0001) while
IL-6 levels peaked at t180 (p < 0.0001). Plasma glucose
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Table 2 Effect of endotoxin on hormones, cytokines and energy metabolism
t0 t60 t120 t180 t240 t360
Control
ACTH (ng/l) 23 ± 7 – 152 ± 66* – 347 ± 204* 36 ± 28
Cortisol (nmol/l) 273 ± 92 – 551 ± 123* – 678 ± 208* 458 ± 222*
Epinephrine (pg/ml) 37 ± 21 – 68 ± 30* – 79 ± 51* 44 ± 15
Norepinephrine (pg/ml) 186 ± 51 – 653 ± 276* – 169 ± 35 176 ± 51
Insulin (mU/ml) 7.7 ± 2.1 8.1 ± 2.4 7.2 ± 1.1 – 7.7 ± 1.6 7.6 ± 1.5
Glucagon (ng/l) 66 ± 22 65 ± 20 94 ± 45* – 103 ± 28* 86 ± 28*
TNF-α (pg/ml) 5.8 ± 8.2 413.1 ± 267.1* 686.9 ± 554.7* 296.2 ± 206.4* 96.2 ± 41.6 –
IL-6 (pg/ml) – 19 ± 30 540 ± 634* 617 ± 642* 237 ± 151 –
hs-CRP (mg/l) 0.4 ± 0.2 – – – – 3.0 ± 0.9
Energy expenditure 1.1 ± 0.2 1.1 ± 0.2 1.4 ± 0.2* 1.5 ± 0.3* 1.5 ± 0.2* 1.3 ± 0.2*
(kcal/min)
Glycemia (mg/dl) 89.3 ± 4.7 88.0 ± 6.0 80.4 ± 8.5* 88.5 ± 6.1 92.3 ± 6.0 93.0 ± 6.3
Lactate (mmol/l) 0.9 ± 0.2 0.9 ± 0.3 1.6 ± 0.4* 1.3 ± 0.4 1.0 ± 0.3 0.9 ± 0.2
Free fatty acids (mmol/l) 0.40 ± 0.12 0.46 ± 0.15 0.75 ± 0.28* 0.84 ± 0.30* 0.97 ± 0.25* 1.03 ± 0.22*
Triglycerides (mmol/l) 0.61 ± 0.21 0.55 ± 0.17 0.58 ± 0.21 0.64 ± 0.25 0.70 ± 0.31 0.60 ± 0.25
Fish oil
ACTH (ng/l) 29 ± 17 – 109 ± 80* – 110 ± 98* 20 ± 12
Cortisol (nmol/l) 205 ± 38 – 441 ± 114* – 529 ± 219* 281 ± 180
Epinephrine (pg/ml) 18 ± 11 – 37 ± 20 – 38 ± 21 33 ± 13
Norepinephrine (pg/ml) 195 ± 77 – 266 ± 78 – 179 ± 56 194 ± 112
Insulin (mU/ml) 10.7 ± 4.0 10.8 ± 3.5 9.9 ± 3.0 – 9.2 ± 2.4 9.4 ± 2.5
Glucagon (ng/l) 65 ± 12 63 ± 11 80 ± 20 – 81 ± 21 72 ± 18
TNF-α (pg/ml) 7.1 ± 8.4 130.5 ± 98.3 255.4 ± 221.5* 118.6 ± 67.2 47.8 ± 29.1 –
IL-6 (pg/ml) – 4.8 ± 10 522 ± 680* 595 ± 900* 227 ± 356 –
hs-CRP (mg/l) 0.5 ± 0.3 – – – – 2.6 ± 1.4
Energy expenditure 1.1 ± 0.1 1.1 ± 0.1 1.2 ± 0.2 1.4 ± 0.3* 1.3 ± 0.2* 1.2 ± 0.2
(kcal/min)
Glycemia (mg/dl) 92.2 ± 5.6 90.6 ± 4.5 85.9 ± 3.2* 91.4 ± 6.5 94.7 ± 8.2 93.8 ± 8.6
Lactate (mmol/l) 1.1 ± 0.3 0.9 ± 0.2 1.2 ± 0.4 1.2 ± 0.6 1.1 ± 0.4 1.0 ± 0.4
Free fatty acids (mmol/l) 0.24 ± 0.11 0.28 ± 0.11 0.33 ± 0.18 0.46 ± 0.18* 0.62 ± 0.26* 0.64 ± 0.22*
Triglycerides (mmol/l) 0.99 ± 0.73 0.87 ± 0.54 0.84 ± 0.42 0.81 ± 0.39* 0.76 ± 0.36* 0.60 ± 0.31*
* p < 0.05, ** p < 0.01 vs. baseline
concentration changes after LPS were not statistically
significant. Plasma lactate increased from t60 and peaked
at t120 (+76%, p = 0.09). A sustained increase in REE
(+38%, p < 0.0001) starting at t90 was observed. FFA
increased significantly from baseline until the end of the
test (+162%, p < 0.0001). Net fat oxidation increased
significantly (+210%, p = 0.001).
Baroreflex sensitivity and heart rate variability
Baroreflex sensitivity decreased significantly between
baseline and the end of the test (p = 0.002). LF power
tended to increased from t30 to t120 and then markedly
decreased at t360 (p = 0.04 from t120 to t360). HF power
remained stable between t30 and t120 and then significantly
decreased at t360 (p = 0.012). The LF/HF ratio, a surrogate
for sympathovagal balance, increased significantly over
time (p < 0.0001).
Effect of FO on the physiological response to LPS
Baseline plasma lipids did not differ: cholesterol
4.4 ± 0.3 mmol/l (control) vs. 4.2 ± 0.3 (FO) and
triglycerides 0.99 ± 0.72 vs. 0.61 ± 0.21 mmol/l. The
triglyceride profile differed during the study between
groups (p < 0.001), with a progressive decrease in the
control groups and stable levels in the FO group in relation
to lipid administration (Table 2). The composition of
platelet membrane was affected by FO infusions, with
significant incorporation of EPA (p = 0.0002) and DHA
(p = 0.02, Fig. 1). Significant differences were observed
in body temperature and the neuroendocrine response
between the FO and control groups. The increase in body
temperature was attenuated in the FO group after LPS:
peak temperature reached 38.1 °C (+1.4 °C) in the FO
group vs. 38.7 °C (+1.9 °C) in controls. The difference
was significant from t120 until t360 (p = 0.003 to p = 0.022;
Fig. 2). The adrenocortical and sympathoadrenal responses
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Fig. 1 Composition of
platelet membrane before and
after fish oil infusion
expressed as percentage of
membrane fatty acids: n-3
PUFA are incorporated into
cell membrane phospholipids
after two doses of fish oil.
(Data available for only five
volunteers due to technical
problems)
Fig. 2 Course of plasma
TNF-α and temperature in the
fish oil and control groups
after LPS injection
to LPS were blunted by FO: the rise in plasma norepi-
nephrine was sevenfold lower (p = 0.02; Fig. 3). Plasma
epinephrine was unchanged. ACTH peak at t240 was four
times lower in the FO group than in controls (p = 0.02).
Plasma cortisol was lower in the FO group but the
difference was not statistically significant (p = 0.07).
TNF-α was also significantly lower in the FO group
between t60 and t180 (p = 0.022 to p = 0.038), but IL-6 val-
ues did not differ between groups. REE variability was
substantial in both groups, particularly in the subjects with
marked shivering (trend to lower REE in the FO group).
Heart rate, cardiac output, respiratory rate, arterial pres-
sure, baroreflex sensitivity, and HRV response to LPS did
not differ between groups.
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Fig. 3 Plasma concentrations
of ACTH and norepinephrine
in the fish oil and control
groups after LPS injection
Discussion
In this human model of intravenous LPS FO lipid emul-
sion blunted important aspects of the response. Fever was
reduced while the hypothalamo-pituitary adrenal and sym-
pathethic responses were blunted. Some aspects of the in-
flammatory response as well as the sympathovagal balance
were altered.
Effects of LPS injection in healthy subjects
Intravenous LPS induces an acute inflammatory state
in healthy humans and animals, which mimics some
pathophysiological aspects of sepsis [8]: a flulike state
rapidly develops, with fever, muscle ache, tachycardia,
sweating, and nausea. Mononuclear cells are activated to
release proinflammatory cytokines, while the complement
and coagulation cascades are activated [9, 10]. A typical
neuroendocrine response transiently occurs. Resting
metabolic rate, glucose turnover, and protein catabolism
are increased [11]. LPS also exerts a demonstrable ef-
fect on HRV, a surrogate parameter of sympathetic and
parasympathetic control on heart rate. Healthy subjects
receiving endotoxin present reduced HRV, as do critical
care patients suffering sepsis [12]. Analysis within the
frequency domain indicates that the LF/HF power ratio
was increased. This observation is usually interpreted as
a marker of sympathetic nerve activity. HRV was affected
by LPS: HF decreased slightly compared to baseline,
suggesting a small change in vagal activity. By contrast,
LF power markedly increased, indicating a consistent in-
crease in sympathetic tone. At the end of the test HF power
decreased, demonstrating a large reduction in parasympa-
thetic activity. Changes in baroreflex sensitivity similarly
reflect the modifications in sympathovagal balance. It is
interesting to observe that baroreflex sensitivity changed
only slightly at t120, whereas it was markedly reduced at
t360. This suggests that under these experimental condi-
tions baroreflex sensitivity is more dependent on changes
in vagal tone than on changes in sympathetic activity.
Effects of n-3 PUFAs on acute inflammation
Various strategies have been used to affect the course
of sepsis in addition to eradication of the septic or in-
flammatory sites. Recent research has focused on the
development of specific nutrients influencing the organ
and system functions as well as the responses to critical
illness [13], such as n-3 PUFAs [1]. FO infusion in guinea
pigs enhances survival following lethal LPS dose [14].
Intravenous FO has been shown to prevent the LPS-
induced reduction in blood flow to the gut and to reduce
bacterial translocation after exposure to live bacteria in
the rat [15]. FO in guinea pigs and rats is associated
with better perfusion in vital organs, improved metabolic
adaptation, and reduced fever and weight loss [15–19].
In a previous study in healthy subjects our group showed
that prolonged supplementation with oral FO blunts
the neuroendocrine and inflammatory responses to LPS
challenge [20]. Perioperative administration of n-3 fatty
acids may favorably affect the postoperative outcome
of surgical patients [21]. Recent data in critically ill
patients suggest that FO supplemented parenteral nutrition
improves survival, infection rate, and length of stay [4].
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Central effects: stress and fever
The response to stress has traditionally been viewed as
a consequence of the neuroendocrine activation, initiated
by tissue injury and by cortical and noncortical signals
from the central nervous system [22]. This response is
characterized by the activation of the sympathoadrenal
system and the hypothalamopituitary axis [23]. In healthy
subjects 3–4 weeks of oral FO inhibited the adrenal acti-
vation elicited by mental stress [24], confirming previous
data in subjects subjected to typhoid vaccine after 6 weeks
of enteral FO [25]. However, the difference in body tem-
perature between FO and saline was not significant, which
limits the evidence. In our experiments FO given before
LPS significantly attenuated fever and stress hormones
production. This is an argument in favor of a central
effect of n-3 PUFAs, downregulating temperature and
sympathetic and adrenocortical axes.
The finding of decreased sympathetic nervous system
activity in our study associated with a lower parasym-
pathetic inhibition after FO may translate into a reduced
arrythmogenic risk. Failure to reach statistical significance
with HRV and baroreflex variability may be related to the
fact these variables are indirect evaluations of sympathetic
activity, with relatively low sensitivity compared to more
direct approaches such as microneurography or plasma
norepinephrine turnover. This result is in agreement with
the significant suppression by FO of plasma norepineph-
rine, a component of sympathetic activation. The relative
inhibition of the central and sympathetic activity and the
adrenal medulla could not be assessed with the present
study design.
Fever is mediated by complex peripheral and central
mechanisms, involving prostaglandin E2, a mediator
derived from arachidonic acid. The latter is produced
in response to cytokines and other mediators. Both in
experimental and clinical settings n-3 PUFA have been
shown to downregulate the temperature response to
inflammation [18, 20, 25]. In our study prostaglandin and
their derivates were not determined, and therefore we
can only speculate that this might have been one of the
underlying mechanisms of fever attenuation.
Inflammatory response
The n-3 PUFAs may modulate the inflammatory re-
sponse by complex mechanisms involving the activity
of transcriptional factors, such as nuclear factor κB,
peroxisome proliferator activated receptors, and sterol
regulatory element binding protein as well as Toll-like
receptors [26]. They also downregulate proinflamma-
tory cytokine production by human monocytes in vitro
and in vivo [27]. In patients undergoing abdominal surgery
provision of parenteral nutrition supplemented with n-3
PUFAs induced decreased levels of plasma TNF-α and
IL-6 in comparison with n-6 fatty acids [28]. In the
present study TNF-α concentrations increase was blunted
in the FO group, confirming an anti-inflammatory effect
of FO. By contrast, IL-6 plasma levels did not differ
between groups, probably due to the short lasting effect of
endotoxin.
Influence of the route of administration
The composition and characteristics of cell membranes is
dependent on the diet composition. In Western populations
the n-3 PUFA content of mononuclear cell membranes is
low, as observed in our healthy volunteers. This may affect
many important cell functions such as membrane fluidity,
opening of ion channels, recognition and function of mem-
brane receptors, eicosanoid synthesis, second messenger
synthesis, and many signaling pathways [29]. In our study
FO was infused to achieve rapid membrane incorporation,
as shown by the rapid increase in the EPA and DHA cell
membrane content. This corresponds to a pharmacological
effect where nutrients are administered to modulate organ
and system functions.
Such rapid delivery of specific compound to the
target cells and organs is difficult to achieve with enteral
administration of triacylglycerols containing long-chain
PUFAs such as DHA and EPA since the hydrolysis of these
compounds by the pancreatic lipase is rather slow. Further-
more, hydrolysis of lipoprotein triacylglycerols by lipopro-
tein lipase is also a slow process with a low efficiency.
As a consequence the use of the intravenous route which
bypasses the intestinal process of absorption and therefore
decreases the delay of action seems attractive. In our study
only two doses of a lipid emulsion containing 10% of FO
significantly modified the cell membrane composition and
the responses to endotoxin. Such a rapid effect may lead
to potential indications for early intervention with FO.
Limitations of the study
The study was designed as a pharmacological investigation
comparing FO lipid emulsion as a drug with no treatment.
Such solution contains glycerol, phosphatidyl-choline, and
some linoleic and linolenic acid and tocopherol in addition
to EPA and DHA. Although these PUFAs were the prin-
cipal components, and their incorporation into platelets
could be confirmed, our results may also be interpreted as
an effect of either of the components of the lipid emulsion.
Finally lipid emulsions have been shown to blunt the
response to LPS in vitro and in vivo [30]. This protection
is achieved through the binding and neutralization of LPS
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by circulating lipoproteins [31]. In our trial the lipoprotein
profile was not determined, and we therefore cannot
conclude on this aspect. Another theoretical limitation is
related to the absence of saline perfusion in the control sub-
jects, to avoid unnecessary cannulations before the study
day. It is seems very unlikely, however, that this design
affected the results considering that basal values were
measured on the day of the test only.
In conclusion, our results indicate that acute intra-
venous FO lipid emulsion administration was rapidly
incorporated into cell membrane and downregulated
the neuroendocrine and metabolic responses to LPS in
healthy humans. This suggests that intravenous FO exerts
beneficial effects in acute medicine by modulating the
stress and inflammatory responses.
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